Pub Date : 2022-01-01DOI: 10.29090/psa.2022.03.21.254
Gajanand R Pujari, V. Subramanian, S. Rao
Neurodegenerative diseases (NDs) are caused by the dysfunction of neurons. Neuronal death is associated with the aggregation of proteins in neurons and glial cells. The aggregated proteins impede mitochondrial function and induce oxidative stress. Increased oxidative stress produces more reactive oxygen species (ROS) which is detrimental to cells in the brain causes neuronal degeneration. There are no treatments for NDs other than reducing disease progression. Hence, the treatment strategies, which reduce oxidative stress and neuronal damage are in demand. Celastrus paniculatus Willd (CP) and Sida cordifolia Linn (SC) have been extensively used in the indigenous therapeutic systems for treating various brain-related ailments. The present investigation was carried out to examine the biochemical and histological alterations of seed oil of CP (SOCP) and aqueous root extract of SC (ARESC) on the hippocampus of the brain in Kainic acid (KA)-induced NDs. The extracts of SOCP and ARESC were administered for 14 days and KA was administered by i.p. on the 14 th day to all the groups except the vehicle control group. At the end of the study, the rat brain was removed, the hippocampus was separated, and the homogenate was prepared to estimate the antioxidant parameters (SOD, catalase, and LPO). LDH assay, dopamine (DA) level, α-synuclein immunohistochemistry, and ROS assays were conducted. The results revealed that the treatment with SOCP and ARESC increased the levels of antioxidant enzymes, reduced oxidative stress, decreased α-synuclein protein aggregation, and elevated the levels of DA neurotransmitters.
{"title":"Neuroprotective role of Celastrus paniculatus Willd and Sida cordifolia Linn on kainic acid-induced neuronal damage in neurodegenerative diseases","authors":"Gajanand R Pujari, V. Subramanian, S. Rao","doi":"10.29090/psa.2022.03.21.254","DOIUrl":"https://doi.org/10.29090/psa.2022.03.21.254","url":null,"abstract":"Neurodegenerative diseases (NDs) are caused by the dysfunction of neurons. Neuronal death is associated with the aggregation of proteins in neurons and glial cells. The aggregated proteins impede mitochondrial function and induce oxidative stress. Increased oxidative stress produces more reactive oxygen species (ROS) which is detrimental to cells in the brain causes neuronal degeneration. There are no treatments for NDs other than reducing disease progression. Hence, the treatment strategies, which reduce oxidative stress and neuronal damage are in demand. Celastrus paniculatus Willd (CP) and Sida cordifolia Linn (SC) have been extensively used in the indigenous therapeutic systems for treating various brain-related ailments. The present investigation was carried out to examine the biochemical and histological alterations of seed oil of CP (SOCP) and aqueous root extract of SC (ARESC) on the hippocampus of the brain in Kainic acid (KA)-induced NDs. The extracts of SOCP and ARESC were administered for 14 days and KA was administered by i.p. on the 14 th day to all the groups except the vehicle control group. At the end of the study, the rat brain was removed, the hippocampus was separated, and the homogenate was prepared to estimate the antioxidant parameters (SOD, catalase, and LPO). LDH assay, dopamine (DA) level, α-synuclein immunohistochemistry, and ROS assays were conducted. The results revealed that the treatment with SOCP and ARESC increased the levels of antioxidant enzymes, reduced oxidative stress, decreased α-synuclein protein aggregation, and elevated the levels of DA neurotransmitters.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90728215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.05.22.175
Sinwisuth Sutheechai, Khanittha Lailakdamrong, P. Sudchada
Several risk prediction models of Contrast-associated acute kidney injury (CA-AKI) in patients undergoing cardiac angiography or angioplasty are available. However, the lack of extensive external validations limits generalizability and clinical acceptance. This study conducted the external validation of three CA-AKI predictive risk models (Chen’s, Inohara’s, and Tziakas’ risk models) and determined the incidence of CA-AKI in Thai patients undergoing cardiac angiography or angioplasty. A total of 647 medical records of patients who underwent elective cardiac angiography (n=446) and angioplasty (n=201) were reviewed. Fifty-five percent were male, mean age 62.6±10.2 years, and mean estimated glomerular filtration rate (eGFR) 69.93±24.30 ml/min/1.73 m2). Incidents of CA-AKI, defined as an absolute increase of serum creatinine of at least 0.3 mg/dL within 48 hours or a relative increase of at least 50% within seven days after the procedure, were collected. The results showed that 78 patients (12.1%) had developed CA-AKI. Chen’s, Inohara’s, and Tziakas’ predictive risk models exhibited low discriminative ability with c-statistic of 0.571, 0.551, and 0.530, respectively. Due to low discriminative capability, these risk models may have low sensitivity to predict CA-AKI in Thai patients undergoing elective cardiac angiography or angioplasty.
{"title":"Performance of contrast-associated acute kidney injury predictive risk models in Thai cardiac angiography or angioplasty patients","authors":"Sinwisuth Sutheechai, Khanittha Lailakdamrong, P. Sudchada","doi":"10.29090/psa.2022.05.22.175","DOIUrl":"https://doi.org/10.29090/psa.2022.05.22.175","url":null,"abstract":"Several risk prediction models of Contrast-associated acute kidney injury (CA-AKI) in patients undergoing cardiac angiography or angioplasty are available. However, the lack of extensive external validations limits generalizability and clinical acceptance. This study conducted the external validation of three CA-AKI predictive risk models (Chen’s, Inohara’s, and Tziakas’ risk models) and determined the incidence of CA-AKI in Thai patients undergoing cardiac angiography or angioplasty. A total of 647 medical records of patients who underwent elective cardiac angiography (n=446) and angioplasty (n=201) were reviewed. Fifty-five percent were male, mean age 62.6±10.2 years, and mean estimated glomerular filtration rate (eGFR) 69.93±24.30 ml/min/1.73 m2). Incidents of CA-AKI, defined as an absolute increase of serum creatinine of at least 0.3 mg/dL within 48 hours or a relative increase of at least 50% within seven days after the procedure, were collected. The results showed that 78 patients (12.1%) had developed CA-AKI. Chen’s, Inohara’s, and Tziakas’ predictive risk models exhibited low discriminative ability with c-statistic of 0.571, 0.551, and 0.530, respectively. Due to low discriminative capability, these risk models may have low sensitivity to predict CA-AKI in Thai patients undergoing elective cardiac angiography or angioplasty.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89484438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.01.21.079
O. Putra, Hardiyono Hardiyono, Mia Arum Anggraini
The impact of immunosuppressant therapy in COVID-19 patients with autoimmune rheumatic disease remains unclear based on previous studies. Here, we reviewed the clinical evidence to evaluate COVID-19 patients with rheumatic disease outcomes, which previously used immunosuppressant therapy to control the disease. We used PubMed and Science Direct database to search literature up to April 2021 for publications with confirmed COVID-19 infection with rheumatic disease. The outcomes of this review were the infection rate of COVID-19 and the rate of hospitalization, ICU admission, and mortality. A total of 16 articles were included in this review. The overall rates of COVID-19 infection in patients with autoimmune rheumatic disease did not differ from the general population. Rheumatic disease patients who previously used hydroxychloroquine showed a similar infection risk of COVID-19 with those who did not use hydroxychloroquine. Furthermore, immunosuppressant therapies were associated with poor clinical outcomes, increase risk of hospitalization, ICU admission, and mortality, particularly in patients with comorbidities. The use of bDMARD, such as TNF-α inhibitor, showed a protective effect to reduce the risk of hospitalization and mortality. The administration of immunosuppressant therapy must be closely monitored in rheumatic disease patients due to unfavorable outcomes. More studies are urgently required to map risk factors of clinical outcomes with the specific immunosuppressant therapy and specific rheumatic disease. [ FROM AUTHOR] Copyright of Pharmaceutical Sciences Asia is the property of Mahidol University, Faculty of Pharmacy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
{"title":"Are immunosuppressant related to unfavorable outcomes in patients COVID-19 with autoimmune rheumatic disease?: A review of clinical evidence","authors":"O. Putra, Hardiyono Hardiyono, Mia Arum Anggraini","doi":"10.29090/psa.2022.01.21.079","DOIUrl":"https://doi.org/10.29090/psa.2022.01.21.079","url":null,"abstract":"The impact of immunosuppressant therapy in COVID-19 patients with autoimmune rheumatic disease remains unclear based on previous studies. Here, we reviewed the clinical evidence to evaluate COVID-19 patients with rheumatic disease outcomes, which previously used immunosuppressant therapy to control the disease. We used PubMed and Science Direct database to search literature up to April 2021 for publications with confirmed COVID-19 infection with rheumatic disease. The outcomes of this review were the infection rate of COVID-19 and the rate of hospitalization, ICU admission, and mortality. A total of 16 articles were included in this review. The overall rates of COVID-19 infection in patients with autoimmune rheumatic disease did not differ from the general population. Rheumatic disease patients who previously used hydroxychloroquine showed a similar infection risk of COVID-19 with those who did not use hydroxychloroquine. Furthermore, immunosuppressant therapies were associated with poor clinical outcomes, increase risk of hospitalization, ICU admission, and mortality, particularly in patients with comorbidities. The use of bDMARD, such as TNF-α inhibitor, showed a protective effect to reduce the risk of hospitalization and mortality. The administration of immunosuppressant therapy must be closely monitored in rheumatic disease patients due to unfavorable outcomes. More studies are urgently required to map risk factors of clinical outcomes with the specific immunosuppressant therapy and specific rheumatic disease. [ FROM AUTHOR] Copyright of Pharmaceutical Sciences Asia is the property of Mahidol University, Faculty of Pharmacy and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"73 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72967588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.05.22.042
Emdormi Rymbai, D. Sugumar, Dhritiman Roy, Divakar Selvaraj
Estrogen receptors are nuclear receptors that play a major role in both physiology and pathology. Estrogen receptor subtypes are currently divided into three groups: estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), and G protein-coupled estrogen receptor 1 (GPER1 or formerly known as GPR30 or GPRx, a membrane-bound receptor). Overexpression of ERα and GPER1 are known to contribute to cancer, with ERα playing the most important impact. On the other hand, it is commonly acknowledged that ERβ inhibits ERα activity and has anti-cancer properties. As a result, the estrogen receptors ERα and ERβ are the most investigated, with ERα being recognized therapeutically as a therapeutic target for breast cancer. Unlike ERα, which must be blocked, ERβ is a target that has anti-cancer properties when activated. The potential anti-cancer efficacy of ERβ has been demonstrated in several pre-clinical and clinical investigations. In this review, we summarize the potential role of ERβ and ERβ agonists in various cancers.
{"title":"Role of estrogen receptors in cancer: a special emphasis on the therapeutic potential of estrogen receptor β","authors":"Emdormi Rymbai, D. Sugumar, Dhritiman Roy, Divakar Selvaraj","doi":"10.29090/psa.2022.05.22.042","DOIUrl":"https://doi.org/10.29090/psa.2022.05.22.042","url":null,"abstract":"Estrogen receptors are nuclear receptors that play a major role in both physiology and pathology. Estrogen receptor subtypes are currently divided into three groups: estrogen receptor alpha (ERα), estrogen receptor beta (ERβ), and G protein-coupled estrogen receptor 1 (GPER1 or formerly known as GPR30 or GPRx, a membrane-bound receptor). Overexpression of ERα and GPER1 are known to contribute to cancer, with ERα playing the most important impact. On the other hand, it is commonly acknowledged that ERβ inhibits ERα activity and has anti-cancer properties. As a result, the estrogen receptors ERα and ERβ are the most investigated, with ERα being recognized therapeutically as a therapeutic target for breast cancer. Unlike ERα, which must be blocked, ERβ is a target that has anti-cancer properties when activated. The potential anti-cancer efficacy of ERβ has been demonstrated in several pre-clinical and clinical investigations. In this review, we summarize the potential role of ERβ and ERβ agonists in various cancers.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79203547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.04.22.041
Kadek Ida Krisnadewi, S. A. Kristina, D. Endarti, T. Andayani
primary health care, and c) work 9 . The same review by Laws R.A (2012) showed efficacy intervention by external validity and behaviors related to preventive programs. The results can generalized from external validity 10 . In this systematic review, the authors evaluate ABSTRACT Studies related to the prevention of diabetes mellitus have developed rapidly, from effectiveness research to implementation research. However, effective implementation of diabetes programs and evidence of their impact on the population should be produced by means other than measuring the effectiveness of the program. We reviewed the results of systematic reviews focused on diabetes prevention programs and the outcomes of those programs in a real-world setting. A systematic review of the program aimed at assessing or measuring the outcome of preventive programs in individual prediabetes, moderate or high-risk diabetes. In September 2021, an article search was performed on PubMed, Science Direct, and SAGE Journal databases. We have reviewed all the articles published in the last ten years. The exclusion criteria were studies published before 2011. The number of diabetic participants is unknown and the method is incomplete. Eight studies were included in the review. All information about participation and programs. Most of all studies were cohort and RCT studies. All interventions showed positive changes (efficacy) based on weight loss, HbA1C, blood glucose levels, and BMI. Rapid studies have shown that the risk of diabetes is reduced. Our results show that the strength of the program plays an important role in the outcome of weight loss. Programs with different variations (education, Community Health worker, diet, physical activity) have had a positive effect on reducing the risk of diabetes in the population.
{"title":"Health interventions and its impact on outcomes among diabetic patients: A systematic review","authors":"Kadek Ida Krisnadewi, S. A. Kristina, D. Endarti, T. Andayani","doi":"10.29090/psa.2022.04.22.041","DOIUrl":"https://doi.org/10.29090/psa.2022.04.22.041","url":null,"abstract":"primary health care, and c) work 9 . The same review by Laws R.A (2012) showed efficacy intervention by external validity and behaviors related to preventive programs. The results can generalized from external validity 10 . In this systematic review, the authors evaluate ABSTRACT Studies related to the prevention of diabetes mellitus have developed rapidly, from effectiveness research to implementation research. However, effective implementation of diabetes programs and evidence of their impact on the population should be produced by means other than measuring the effectiveness of the program. We reviewed the results of systematic reviews focused on diabetes prevention programs and the outcomes of those programs in a real-world setting. A systematic review of the program aimed at assessing or measuring the outcome of preventive programs in individual prediabetes, moderate or high-risk diabetes. In September 2021, an article search was performed on PubMed, Science Direct, and SAGE Journal databases. We have reviewed all the articles published in the last ten years. The exclusion criteria were studies published before 2011. The number of diabetic participants is unknown and the method is incomplete. Eight studies were included in the review. All information about participation and programs. Most of all studies were cohort and RCT studies. All interventions showed positive changes (efficacy) based on weight loss, HbA1C, blood glucose levels, and BMI. Rapid studies have shown that the risk of diabetes is reduced. Our results show that the strength of the program plays an important role in the outcome of weight loss. Programs with different variations (education, Community Health worker, diet, physical activity) have had a positive effect on reducing the risk of diabetes in the population.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81412381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.05.22.001
N. Frimayanti, Marzieh Yaeghoobi, Hamid Namavar, Mashitoh Cindy Utari, Meiriza Djohari, Cindy Oktaviana Laia
Combination of similarity searching with docking and molecular dynamic simulations were performed. In this study, chalcone-based 1,5-benzothiazepine compound (i.e. MA9) was used as parent compound, since it exhibits potential enhancement and improvement of biological activity over doxorubicin (i.e. the common agent for cancer treatment). The main aim of this study was to explore a new potential inhibitor against breast cancer from a large database. To study this effect, several computational approaches were applied. Initially, seven compounds were observed according to the Euclidean distance and Tanimoto coefficient. Parent compound and all these seven compounds were docked into 1T46 protein active site. Docking results reported that ZINC4377306 and ZINC4377309 have exhibited binding free energy of -6.75 and -6.49 kcal/mol, respectively. In addition, they showed the binding interaction through hydrogen bond, van der Waals and other interactions with the notable residues around the active site. Both compounds were stable during the molecular dynamic simulation. Thus, ZINC4377306 and ZINC4377309 can be used as new potential agents against breast cancer as an early stage in drug discovery process.
{"title":"In silico analysis approach for screening new agents for breast cancer inhibitors based on 1,5-benzothiazepine","authors":"N. Frimayanti, Marzieh Yaeghoobi, Hamid Namavar, Mashitoh Cindy Utari, Meiriza Djohari, Cindy Oktaviana Laia","doi":"10.29090/psa.2022.05.22.001","DOIUrl":"https://doi.org/10.29090/psa.2022.05.22.001","url":null,"abstract":"Combination of similarity searching with docking and molecular dynamic simulations were performed. In this study, chalcone-based 1,5-benzothiazepine compound (i.e. MA9) was used as parent compound, since it exhibits potential enhancement and improvement of biological activity over doxorubicin (i.e. the common agent for cancer treatment). The main aim of this study was to explore a new potential inhibitor against breast cancer from a large database. To study this effect, several computational approaches were applied. Initially, seven compounds were observed according to the Euclidean distance and Tanimoto coefficient. Parent compound and all these seven compounds were docked into 1T46 protein active site. Docking results reported that ZINC4377306 and ZINC4377309 have exhibited binding free energy of -6.75 and -6.49 kcal/mol, respectively. In addition, they showed the binding interaction through hydrogen bond, van der Waals and other interactions with the notable residues around the active site. Both compounds were stable during the molecular dynamic simulation. Thus, ZINC4377306 and ZINC4377309 can be used as new potential agents against breast cancer as an early stage in drug discovery process.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81291902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.01.21.045
Naglaa I. Afifi, A. Moawad, M. Hetta, R. Mohammed
The role of natural products as remedies has been recognized since ancient times. Demand for medicinal plants is increasing in both developed and developing countries due to growing recognition of natural products as being safer and having a potential of large benefits to society. Egyptian flora, being variable, has become an interesting spot to prospect for new chemical leads. So, in recent decades, many studies have been carried out on different plant species to discover compounds of possible interest for different medicinal applications. Among these studies, several have focused on the biological and phytochemical properties of different species of the family Arecaceae. Arecaceae is among the famous plant families which include genera that introduce phenolicrich species. Previous phytochemical investigations have shown that flavonoids, anthocyanidins, lignans, benzenoids, benzoquinone, monoterpenoids, and nor isoprenoids are constituents of family Arecaceae. Archontophoenix alexandrae is known as Alexander palm, king Alexander palm, king palm and northern bangalow palm. It is endemic to northern Queensland and Australia and occurs in the rainforests of tropical and warm temperate regions. It is often used as an ornamental plant. Dictyosperma album has two common names; princess palm and hurricane palm. It is native to Reunion and Mauritius. The root decoction of Dictyosperma album is used as diuretic. It was reported that Archontophoenix alexandrae (Wendl. & Drude) and Dictyosperma album (Bory) H.Wendl. & Drude ex Scheff.; family Arecaceae; contain glycoflavones; being with few reports on their chemical constituents; motivated us to investigate their phytochemical constituents and their antioxidant activity.
{"title":"Phytochemical composition and antioxidant activity of two species related to family Arecaceae","authors":"Naglaa I. Afifi, A. Moawad, M. Hetta, R. Mohammed","doi":"10.29090/psa.2022.01.21.045","DOIUrl":"https://doi.org/10.29090/psa.2022.01.21.045","url":null,"abstract":"The role of natural products as remedies has been recognized since ancient times. Demand for medicinal plants is increasing in both developed and developing countries due to growing recognition of natural products as being safer and having a potential of large benefits to society. Egyptian flora, being variable, has become an interesting spot to prospect for new chemical leads. So, in recent decades, many studies have been carried out on different plant species to discover compounds of possible interest for different medicinal applications. Among these studies, several have focused on the biological and phytochemical properties of different species of the family Arecaceae. Arecaceae is among the famous plant families which include genera that introduce phenolicrich species. Previous phytochemical investigations have shown that flavonoids, anthocyanidins, lignans, benzenoids, benzoquinone, monoterpenoids, and nor isoprenoids are constituents of family Arecaceae. Archontophoenix alexandrae is known as Alexander palm, king Alexander palm, king palm and northern bangalow palm. It is endemic to northern Queensland and Australia and occurs in the rainforests of tropical and warm temperate regions. It is often used as an ornamental plant. Dictyosperma album has two common names; princess palm and hurricane palm. It is native to Reunion and Mauritius. The root decoction of Dictyosperma album is used as diuretic. It was reported that Archontophoenix alexandrae (Wendl. & Drude) and Dictyosperma album (Bory) H.Wendl. & Drude ex Scheff.; family Arecaceae; contain glycoflavones; being with few reports on their chemical constituents; motivated us to investigate their phytochemical constituents and their antioxidant activity.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"93 5 Pt 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77580441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.06.22.141
N. Sae-lim, Ploylarp Lertvipapath
A retrospective observational study of 1,160 prescriptions with prescribing errors from a large academic hospital in Thailand from 2014 to 2017. The aims of this study are to explore the proportion of prescribing error from pre-printed prescriptions and measure the frequency of prescribing errors in pre-printed versus hand-written prescriptions. Prescriptions with prescribing errors were stratified sampling and bootstrap resampling, then classified into 1) pre-printed historical medication prescriptions or pre-printed prescriptions 2) hand-written prescriptions. Some missed prescribing errors of each type of prescription were more identified by comparing the prescriptions with the medical records. Pre-printed prescriptions with prescribing errors constituted 767 (66%) of all collected prescriptions. The most commonly encountered prescribing error was “incomplete medication list in medical record”, while 393 (34%) hand-written prescriptions were found to have the wrong dosage strength. Hand-written prescriptions were 1.45 times more likely to have a major error compared to pre-printed prescriptions (OR: 1.45, 95%CI: 1.08-1.94, P 0.012). Although using pre-printed prescription can reduce some prescribing errors such as wrong dosage strength that occur with hand-written prescriptions, pre-printed prescriptions were found to have other prescribing errors. Procedures to improve the prescribing system to increase patient safety are needed.
回顾性观察研究泰国某大型学术医院2014 - 2017年处方错误处方1160张。本研究的目的是探讨预印处方的处方错误比例，并测量预印处方与手写处方的处方错误频率。对处方有误的处方进行分层抽样和自举重抽样，将处方分为预印历史用药处方和预印处方2手写处方。通过对比处方与病历，更能识别出各类处方的一些漏开错误。处方错误的预印处方占收集处方的767张(66%)。最常见的处方错误是“病历中用药清单不完整”，393张(34%)手写处方存在剂量强度错误。手写处方出现重大错误的可能性是预印处方的1.45倍(OR: 1.45, 95%CI: 1.08-1.94, P 0.012)。虽然使用预印处方可以减少一些处方错误，如手写处方出现的剂量强度错误，但预印处方也存在其他处方错误。需要改进处方系统以提高患者安全的程序。
{"title":"Study of prescribing errors of two different prescription systems: pre-printed prescription from historical medication and hand-written prescription","authors":"N. Sae-lim, Ploylarp Lertvipapath","doi":"10.29090/psa.2022.06.22.141","DOIUrl":"https://doi.org/10.29090/psa.2022.06.22.141","url":null,"abstract":"A retrospective observational study of 1,160 prescriptions with prescribing errors from a large academic hospital in Thailand from 2014 to 2017. The aims of this study are to explore the proportion of prescribing error from pre-printed prescriptions and measure the frequency of prescribing errors in pre-printed versus hand-written prescriptions. Prescriptions with prescribing errors were stratified sampling and bootstrap resampling, then classified into 1) pre-printed historical medication prescriptions or pre-printed prescriptions 2) hand-written prescriptions. Some missed prescribing errors of each type of prescription were more identified by comparing the prescriptions with the medical records. Pre-printed prescriptions with prescribing errors constituted 767 (66%) of all collected prescriptions. The most commonly encountered prescribing error was “incomplete medication list in medical record”, while 393 (34%) hand-written prescriptions were found to have the wrong dosage strength. Hand-written prescriptions were 1.45 times more likely to have a major error compared to pre-printed prescriptions (OR: 1.45, 95%CI: 1.08-1.94, P 0.012). Although using pre-printed prescription can reduce some prescribing errors such as wrong dosage strength that occur with hand-written prescriptions, pre-printed prescriptions were found to have other prescribing errors. Procedures to improve the prescribing system to increase patient safety are needed.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86856539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-01DOI: 10.29090/psa.2022.04.21.157
Seham El-Hawary El-Hawary, R. Mohammed, M. Taher, S. AbouZid, Elham Amin
Tabebuia is the largest genus of the Bignoniaceae family, with great importance due to its beautiful decorative flowering trees, as well as, its remarkable biological activities. The exact identification of Tabebuia species is important, not only, for cultivation purposes but also for exploration of their phytochemical and biological potential. DNA fingerprinting technology is now considered an easily accessible, quick, and accurate method of species identification. The current study investigated the genetic diversity among five Tabebuia species, using start codon targeted (SCoT), and inter simple sequence repeats (ISSR) markers. Results indicated the efficiency of both markers for genetic fingerprinting of the five tested Tabebuia species with ISSR analysis being more polymorphic than SCoT analysis. The dendrogram generated from the combination of ISSR and SCoT analyses classified the tested species into two main clusters. Cluster I included T. guayacan , while Cluster II was separated into sub-cluster I comprising T. rosea and sub-cluster II that was further subdivided into sub-cluster IIa ( T. pulcherrima ) and sub-cluster IIb ( T. argentea and T. pallida ). Furthermore, the antitrypanosomal activity of the alcohol extracts of stems and leaves of the five tested Tabebuia was evaluated. Results revealed a variation in activity between extracts from different species. The highest antitrypanosomal activity was recorded for the stem and leaf extracts from T. with IC 50 (6.4-7.2 µg/mL) and (8.3 and 8.9 µg/mL) after 48 and 72 h respectively, followed by T. pallida leaf then T. rosea stem extracts.
大戟属是大戟科中最大的属，因其美丽的装饰性开花树木和显著的生物活性而具有重要意义。准确鉴定Tabebuia的种类不仅对种植目的很重要，而且对探索其植物化学和生物学潜力也很重要。DNA指纹技术现在被认为是一种容易获得、快速和准确的物种鉴定方法。本研究利用起始密码子靶向(SCoT)和简单序列重复(ISSR)标记对5种塔贝布亚属植物的遗传多样性进行了研究。结果表明，两种标记的ISSR遗传指纹分析效率均高于SCoT遗传指纹分析的多态性。结合ISSR和SCoT分析生成的树形图将被测物种分为两个主要聚类。聚类I包括瓜亚番石榴，聚类II分为亚聚类I和亚聚类II，亚聚类II再细分为亚聚类IIa (T. pulcherrima)和亚聚类IIb (T. argenttea和T. pallida)。此外，还对五种被试植物的茎叶醇提取物的抗锥虫活性进行了评价。结果显示，不同种类提取物的活性存在差异。在48 h和72 h后，以ic50(6.4 ~ 7.2µg/mL)和ic50(8.3和8.9µg/mL)的黄芪茎和叶提取物的抗锥虫活性最高，其次是白芷叶，其次是玫瑰红茎提取物。
{"title":"DNA fingerprinting of five Tabebuia species with reference to their anti-trypanosomal activity","authors":"Seham El-Hawary El-Hawary, R. Mohammed, M. Taher, S. AbouZid, Elham Amin","doi":"10.29090/psa.2022.04.21.157","DOIUrl":"https://doi.org/10.29090/psa.2022.04.21.157","url":null,"abstract":"Tabebuia is the largest genus of the Bignoniaceae family, with great importance due to its beautiful decorative flowering trees, as well as, its remarkable biological activities. The exact identification of Tabebuia species is important, not only, for cultivation purposes but also for exploration of their phytochemical and biological potential. DNA fingerprinting technology is now considered an easily accessible, quick, and accurate method of species identification. The current study investigated the genetic diversity among five Tabebuia species, using start codon targeted (SCoT), and inter simple sequence repeats (ISSR) markers. Results indicated the efficiency of both markers for genetic fingerprinting of the five tested Tabebuia species with ISSR analysis being more polymorphic than SCoT analysis. The dendrogram generated from the combination of ISSR and SCoT analyses classified the tested species into two main clusters. Cluster I included T. guayacan , while Cluster II was separated into sub-cluster I comprising T. rosea and sub-cluster II that was further subdivided into sub-cluster IIa ( T. pulcherrima ) and sub-cluster IIb ( T. argentea and T. pallida ). Furthermore, the antitrypanosomal activity of the alcohol extracts of stems and leaves of the five tested Tabebuia was evaluated. Results revealed a variation in activity between extracts from different species. The highest antitrypanosomal activity was recorded for the stem and leaf extracts from T. with IC 50 (6.4-7.2 µg/mL) and (8.3 and 8.9 µg/mL) after 48 and 72 h respectively, followed by T. pallida leaf then T. rosea stem extracts.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83547336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Androgen receptor signaling inhibitor (ARSI) therapy plays an important role in treating advanced prostate cancer. However, in Thailand, the efficacy and safety data of ARSI therapy remain limited. This study aimed to assess the efficacy and safety of ARSI therapy to treat patients with metastatic castration naïve prostate cancer. We collected data from electronic medical records based on disease progression and any reported adverse events. The primary outcome was progression-free survival (PFS) after initiating ARSI therapy. Secondary outcome was PFS according to abiraterone and enzalutamide, risk factors associated with PFS of ARSI therapy and adverse events. A total of 49 eligible patients were enrolled having received ARSI therapy (abiraterone or enzalutamide) to treat metastatic prostate cancer. The median time to follow-up was 17 months (interquartile range, 12-31). PFS among patients treated with ARSI therapy was 22 months (95% confidence interval [CI], 17-33), PFS among patients with abiraterone and enzalutamide was 21 and 23 months, respectively (hazard ratio [HR], 0.48; 95% CI, 0.17-1.41, P =0.185). Patients with Eastern Cooperative Group status 1-2 exhibited significantly decreased risk of disease progression (HR, 0.44; 95% CI, 0.20-0.96, P =0.038). The common adverse events included hypertension and fluid retention and edema. In conclusion, abiraterone and enzalutamide showed a trend to improve PFS among patients with metastatic castration naïve prostate cancer. Adverse events were rarely reported, and patients were able to tolerate treatment.
雄激素受体信号抑制剂(ARSI)治疗在晚期前列腺癌的治疗中发挥着重要作用。然而，在泰国，ARSI治疗的有效性和安全性数据仍然有限。本研究旨在评估ARSI治疗转移性去势naïve前列腺癌患者的疗效和安全性。我们根据疾病进展和任何报告的不良事件从电子病历中收集数据。主要终点是开始ARSI治疗后的无进展生存期(PFS)。次要结局是根据阿比特龙和恩杂鲁胺的PFS，与ARSI治疗PFS相关的危险因素和不良事件。共有49名符合条件的患者接受了ARSI治疗(阿比特龙或恩杂鲁胺)来治疗转移性前列腺癌。中位随访时间为17个月(四分位数间距12-31)。ARSI治疗患者的PFS为22个月(95%可信区间[CI]， 17-33)，阿比特龙和恩杂鲁胺治疗患者的PFS分别为21和23个月(风险比[HR]， 0.48;95% ci, 0.17-1.41, p =0.185)。东部合作组状态1-2的患者疾病进展风险显著降低(HR, 0.44;95% ci, 0.20-0.96, p =0.038)。常见的不良事件包括高血压、液体潴留和水肿。总之，阿比特龙和恩杂鲁胺有改善转移性去势naïve前列腺癌患者PFS的趋势。不良事件很少报道，患者能够耐受治疗。
{"title":"Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer","authors":"Jukapun Yoodee, Chiraphon Detma, Onuma Lappanawan, Worachaya Pengthina","doi":"10.29090/psa.2022.06.22.236","DOIUrl":"https://doi.org/10.29090/psa.2022.06.22.236","url":null,"abstract":"Androgen receptor signaling inhibitor (ARSI) therapy plays an important role in treating advanced prostate cancer. However, in Thailand, the efficacy and safety data of ARSI therapy remain limited. This study aimed to assess the efficacy and safety of ARSI therapy to treat patients with metastatic castration naïve prostate cancer. We collected data from electronic medical records based on disease progression and any reported adverse events. The primary outcome was progression-free survival (PFS) after initiating ARSI therapy. Secondary outcome was PFS according to abiraterone and enzalutamide, risk factors associated with PFS of ARSI therapy and adverse events. A total of 49 eligible patients were enrolled having received ARSI therapy (abiraterone or enzalutamide) to treat metastatic prostate cancer. The median time to follow-up was 17 months (interquartile range, 12-31). PFS among patients treated with ARSI therapy was 22 months (95% confidence interval [CI], 17-33), PFS among patients with abiraterone and enzalutamide was 21 and 23 months, respectively (hazard ratio [HR], 0.48; 95% CI, 0.17-1.41, P =0.185). Patients with Eastern Cooperative Group status 1-2 exhibited significantly decreased risk of disease progression (HR, 0.44; 95% CI, 0.20-0.96, P =0.038). The common adverse events included hypertension and fluid retention and edema. In conclusion, abiraterone and enzalutamide showed a trend to improve PFS among patients with metastatic castration naïve prostate cancer. Adverse events were rarely reported, and patients were able to tolerate treatment.","PeriodicalId":19761,"journal":{"name":"Pharmaceutical Sciences Asia","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83788828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：